Cardiogenesis gets transmyocardial laser revascularisation (TMR) trial go-ahead
This article was originally published in Clinica
Executive Summary
Cardiogenesis plans to enrol up to 500 patients in a US trial of transmyocardial laser revascularisation (TMR). The company has received an IDE to compare combined bypass surgery and adjunctive TMR with bypass alone in patients who cannot be completely revascularised by surgery, in a randomised, prospective, blinded, multi-centre trial.